News Sentiment

TNYA sentiment intelligence

Tenaya Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.87 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

+10.6% over one week, +22.3% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

Tenaya’s new CFO gets options on 1.65M shares, with a $0.8365 exercise price

Market Reaction

Price moving ahead of tone

68/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction 10.6% Price confirming higher
Trend fit Trend active 22.3% over four weeks
Fair value -58.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 22
Neutral 33
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 15
Stock Titan 10
simplywall.st 5
GlobeNewswire 4
Moomoo 4
Investing News Network 3
TradingView 3
TradingKey 3

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 17
Analyst action 4
Balance sheet 2
Deals and strategy 2
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 58
Stock Titan Direct company coverage

Tenaya’s new CFO gets options on 1.65M shares, with a $0.8365 exercise price

Tenaya Therapeutics (NASDAQ:TNYA) granted stock options to its newly appointed CFO, Eric Hyllengren, for 1.65 million shares, and an additional 187,200 shares to two non-executive employees. These inducement grants, made under the company's 2024 Inducement Equity Incentive Plan,

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 02:41
Source
Stock Titan
Stock Titan Direct company coverage

Tenaya Therapeutics (TNYA) grants CFO 1,650,000 stock options

Tenaya Therapeutics (TNYA) granted its Chief Financial Officer, Eric J. Hyllengren, a stock option for 1,650,000 shares of common stock with an exercise price of $0.8365 per share. This option was issued under the 2024 Inducement Equity Incentive Plan, will vest 25% after one yea

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 01:41
Source
Stock Titan
Stock Titan Direct company coverage

Tenaya Therapeutics (TNYA) CFO files first Form 3 ownership report

Tenaya Therapeutics, Inc.'s Chief Financial Officer, Eric J Hyllengren, has filed an initial Form 3 insider ownership report. The filing indicates no buy or sell transactions, no derivative positions, and a neutral net buy/sell status. This Form 3 establishes Hyllengren as an ins

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 01:41
Source
Stock Titan
GlobeNewswire Direct company coverage

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Tenaya Therapeutics (NASDAQ: TNYA) announced inducement grants of stock options to its new Chief Financial Officer, Eric Hyllengren, and two other non-executive employees. The grants, totaling 1,650,000 shares for Hyllengren and 187,200 for other employees, were made in accordanc

Tone
Positive 60/100
Event
Market update
Published
15 Jul 2026 00:41
Source
GlobeNewswire
Finviz Direct company coverage

TNYA - Tenaya Therapeutics Inc Options

This article provides a detailed financial overview of Tenaya Therapeutics Inc (TNYA), including its stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. The company closed at $0.7869, showing a 5.50% increase, and has a mark

Tone
Neutral 50/100
Event
Analyst action
Published
03 Jul 2026 19:10
Source
Finviz
Simply Wall Street Direct company coverage

Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) Path To Profitability

Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company, is projected by analysts to reach profitability by 2028, with a forecasted profit of US$121 million after incurring a final loss in 2027. This breakeven projection relies on a very high annual growth

Tone
Positive 77/100
Event
Earnings
Published
03 Jul 2026 11:41
Source
Simply Wall Street
Stock Titan Direct company coverage

Tenaya Therapeutics (NASDAQ: TNYA) exits Union City manufacturing lease, shifts to CDMO

Tenaya Therapeutics has terminated its lease for the Genetic Medicines Manufacturing Center in Union City, California, originally set to run until July 2031, now ending on August 31, 2026. The company will forfeit a $1.75 million security deposit and pay a termination fee of appr

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 20:40
Source
Stock Titan
Investing News Network Direct company coverage

Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer

Tenaya Therapeutics, a clinical-stage biotechnology company focused on heart disease therapies, announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 13, 2026. He will oversee financial strategy, capital allocation, investor relations, and corpor

Tone
Positive 70/100
Event
Market update
Published
30 Jun 2026 07:40
Source
Investing News Network
Moomoo Direct company coverage

Press Release: Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer

Tenaya Therapeutics has announced the appointment of Eric Hyllengren as its new Chief Financial Officer. This key leadership addition is expected to bolster the company's financial strategy and operations as it continues to advance its therapeutic pipeline.

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 18:40
Source
Moomoo
Stock Titan Direct company coverage

Eric Hyllengren to lead finances at Tenaya Therapeutics (NASDAQ: TNYA)

Tenaya Therapeutics (NASDAQ: TNYA) has appointed Eric Hyllengren as its new Chief Financial Officer, effective July 13, 2026. He will also serve as Principal Financial Officer and Principal Accounting Officer, bringing over two decades of biotech finance experience. His compensat

Tone
Positive 65/100
Event
Market update
Published
29 Jun 2026 13:12
Source
Stock Titan
Stock Titan Direct company coverage

Tenaya Therapeutics taps biotech finance veteran as CFO

Tenaya Therapeutics (NASDAQ:TNYA) has appointed Eric Hyllengren as its new Chief Financial Officer, effective July 13, 2026. Hyllengren brings over 20 years of experience in biotech finance, having previously held CFO roles at Zura Bio and Atara Biotherapeutics, where he secured

Tone
Positive 66/100
Event
Market update
Published
29 Jun 2026 12:12
Source
Stock Titan
TradingView Direct company coverage

Price to sales forward of Tenaya Therapeutics, Inc. – NASDAQ:TNYA

The article provides a financial data point for Tenaya Therapeutics, Inc. (NASDAQ: TNYA), specifically its forward price to sales ratio. It appears to be a stub or a section from a larger financial data platform like TradingView, given the limited content and extensive navigation

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 05:40
Source
TradingView
TradingView Direct company coverage

Price to book forward of Tenaya Therapeutics, Inc. – NASDAQ:TNYA

The article discusses the "Price to book forward" metric for Tenaya Therapeutics, Inc. (NASDAQ: TNYA) on TradingView. It appears to be a financial data point without further analysis or specific values presented in the provided content. The surrounding text indicates this is a fi

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 00:41
Source
TradingView
TradingKey Direct company coverage

Tenaya Therapeutics Inc (TNYA) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Tenaya Therapeutics Inc (TNYA) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and shows no data for past stock splits. The page also includes current stock quotes and ke

Tone
Neutral 50/100
Event
Capital return
Published
18 Jun 2026 09:10
Source
TradingKey
Quartr Direct company coverage

Tenaya Therapeutics (TNYA) Jefferies Global Healthcare Conference 2026 Summary

Tenaya Therapeutics (TNYA) presented at the Jefferies Global Healthcare Conference 2026, outlining its strategic focus on developing curative therapies for heart disease using gene therapy, small molecules, and gene editing. The company highlighted three clinical-stage programs:

Tone
Positive 81/100
Event
Market update
Published
18 Jun 2026 08:10
Source
Quartr
TradingKey Direct company coverage

Tenaya Therapeutics Inc (TNYA) Institutional Confidence

This article provides an "Institutional Confidence" overview for Tenaya Therapeutics Inc (TNYA), detailing key shareholder activities and holdings. It lists major institutional investors, their share counts, and percentage changes in their holdings. The report is part of a broade

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 05:10
Source
TradingKey
TradingKey Direct company coverage

Tenaya Therapeutics Inc (TNYA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article concerns Tenaya Therapeutics Inc's (TNYA) revenue breakdown. It states that relevant data regarding the company's business segments, regional revenue, and profit contribution have not yet been disclosed by the company. As such, the article provides a placeholder for

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 22:09
Source
TradingKey
Moomoo Direct company coverage

Morgan Stanley Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $2

Morgan Stanley has reiterated its "Buy" rating for Tenaya Therapeutics (TNYA.US), maintaining a target price of $2. This continued endorsement suggests the firm's confidence in the company's future performance. The maintained rating and price target indicate a consistent positive

Tone
Positive 71/100
Event
Analyst action
Published
04 Jun 2026 22:40
Source
Moomoo
Market source Direct company coverage

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms

Tenaya Therapeutics has released promising interim data from its MyPEAK™-1 clinical trial for TN-201 gene therapy, targeting MYBPC3-associated hypertrophic cardiomyopathy (HCM). The results indicate consistent cardiac remodeling, reductions in symptoms, and improved exercise capa

Tone
Positive 80/100
Event
Earnings
Published
03 Jun 2026 23:10
Source
Market source
Investing News Network Direct company coverage

Tenaya Therapeutics to Announce New Interim Data from MyPEAK-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026

Tenaya Therapeutics will present new interim data from Cohort 1 and 2 of its MyPEAK-1 Phase 1b/2 trial for TN-201 gene therapy in adults with MYBPC3-associated hypertrophic cardiomyopathy (HCM) on June 3, 2026. This genetic condition impacts approximately 120,000 patients in the

Tone
Positive 67/100
Event
Market update
Published
03 Jun 2026 21:39
Source
Investing News Network
Quiver Quantitative Direct company coverage

Tenaya Therapeutics to Report Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 Gene Therapy for HCM on June 3, 2026

Tenaya Therapeutics will present new interim data from its MyPEAK™-1 Phase 1b/2 trial of TN-201 gene therapy for adults with MYBPC3-associated hypertrophic cardiomyopathy (HCM) on June 3, 2026. This gene therapy aims to deliver a working MYBPC3 gene to heart cells, addressing the

Tone
Positive 59/100
Event
Market update
Published
03 Jun 2026 19:39
Source
Quiver Quantitative
BioPharm International Direct company coverage

Tenaya Reports Interim TN-201 Data in MYBPC3-Associated HCM

Tenaya Therapeutics' interim phase 1b/2 data for TN-201 gene therapy in MYBPC3-associated hypertrophic cardiomyopathy (HCM) showed promising results. The treatment was well-tolerated and led to improvements in cardiac remodeling, symptom burden, and functional measures in evaluab

Tone
Positive 74/100
Event
Earnings
Published
03 Jun 2026 12:40
Source
BioPharm International
GlobeNewswire Direct company coverage

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1

Tenaya Therapeutics reported positive interim safety and efficacy data from its MyPEAK™-1 Phase 1b/2 clinical trial for TN-201, a gene therapy targeting MYBPC3-associated hypertrophic cardiomyopathy (HCM). The data showed improvements in cardiac remodeling, reduced symptoms, and

Tone
Positive 72/100
Event
Market update
Published
03 Jun 2026 11:09
Source
GlobeNewswire
Stock Titan Direct company coverage

Gene therapy eases genetic heart condition in small Tenaya trial

Tenaya Therapeutics reported positive interim results from its MyPEAK-1 Phase 1b/2 clinical trial for TN-201 gene therapy in MYBPC3-associated hypertrophic cardiomyopathy (HCM). Six evaluable patients showed consistent cardiac remodeling, reductions in left ventricular mass, impr

Tone
Positive 71/100
Event
Earnings
Published
03 Jun 2026 11:09
Source
Stock Titan
Seeking Alpha Direct company coverage

Tenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy for MYBPC3-Associated HCM - Slideshow (NASDAQ:TNYA)

Tenaya Therapeutics (TNYA) discussed interim data from its MyPEAK-1 trial for TN-201, a gene therapy targeting MYBPC3-associated hypertrophic cardiomyopathy (HCM). The company published a slide deck in conjunction with this event, detailing the findings. This update provides insi

Tone
Positive 68/100
Event
Market update
Published
03 Jun 2026 09:52
Source
Seeking Alpha